Meridian Bioscience Acquired by SD Biosensor and SJL Partners

By LabMedica International staff writers
Posted on 08 Jul 2022

Meridian Bioscience, Inc. (Cincinnati, OH, USA) and SD Biosensor, Inc. (SDB, Seoul, South Korea) and SJL Partners LLC (SJL, Seoul, South Korea) (collectively referred to as the consortium) have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the consortium will acquire Meridian in an all-cash transaction valued at approximately USD 1.53 billion. The consortium intends to operate Meridian as an independent entity following the completion of the transaction.

"This announcement follows an extensive and deliberate review of Meridian's growth and value creation opportunities in the context of the broader macroeconomic and industry environment," said John C. McIlwraith, Meridian's Chairman. "In consultation with external financial advisors and following outreach to potential strategic and financial partners, the Board unanimously agreed that this transaction represents the best path forward for Meridian shareholders, providing them with immediate, compelling and certain value, while enabling the company to benefit from SDB's and SJL's capital support, expertise and experience."

Image: Meridian has been acquired in a USD 1.53 billion all-cash transaction (Photo courtesy of Meridian Bioscience)

"We are excited to announce this new chapter for Meridian after the many years spent transforming the company for sustainable growth," commented Jack Kenny, Meridian's Chief Executive Officer. "In addition to delivering immediate and significant value to our shareholders, we believe the transaction will enhance our ability to serve customers as we navigate the decline in COVID-19 testing demand and develop new products with the benefit of SDB's industry expertise and complementary offerings. Current and prospective employees around the world will also benefit from an even stronger Meridian supported by SDB's and SJL's financial backing and experience. I look forward to working with SDB and SJL and the rest of our Meridian team to build long-term strength and drive further growth in the diagnostics space."

"We are pleased to be a family with Meridian Bioscience as a great partner for accelerating our entry into the U.S. IVD market. I believe that SD Biosensor's R&D capabilities and mass production know-how, Meridian Bioscience's U.S. distribution network and expertise in the regulated U.S. market, and SJL Partners' strong management expertise will enable compelling synergies," added Dr. Young Shik Cho, Chairman of SDB, representing the consortium.

"We are eager to begin this partnership with the Meridian team. The combination of Meridian's product commercialization team with deep expertise in the regulated U.S. market, SDB's broad product portfolio and scale manufacturing expertise, and SJL's execution experience and partnership model will further position the company for long-term success," said Steve Sukjung Lim, Chairman and Managing Partner of SJL.